EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 530 participants.

Also called NCT05151172

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 530 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05151172
Other papers using this trial's data
  • Thrombectomy for Acute Stroke Due to Medium Vessel Occlusion Across Perfusion Mismatch Profiles: A Post Hoc Analysis of the ESCAPE-MeVO Trial JAMA network open, 2026-10-01 DOI, PubMed 42867860, PMC13662659 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Germany, United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05151172. Randomized; single masking; primary purpose treatment. Start 2022-04-15 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)
Acronym
ESCAPE-MeVO
Condition
Acute Ischemic Stroke
Intervention (Device)
endovascular thrombectomy (EVT)
Intervention (Other)
Standarad medical care
Lead sponsor
Dr. Michael D Hill (class: other)
Collaborator
University of Calgary (class: other)

Record details

Record id
cardio:ct-nct05151172
Content hash
3ef36c77ea7aa7e26a8425f58f6fbe1de9344222f9ff6721e2e6a33898d3f989